asa glp-1 agonists The 2023 position on receptor has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on Perioperative Considerations for Patients on

Your safety drives that decision, not your previous plan

declares additional funding for this work through the UK Medical Research Council (MRC) (MR/T033371/1), and NIHR Development and Skills Enhancement Award (NIHR301616)

Importantly, sDPP-4 levels do not correlate with fasting blood glucose levels (67, 68)

These receptors, expressed on pancreatic cells, when activated, augment insulin secretion [49]

The mean patient age ranged between 34 and 57 years

These findings support the continued use of GLP-1 receptor agonists for approved metabolic indications, while acknowledging that the certainty of evidence varies by cancer site